Application of 18 beta-glycyrrhetinic acid (or salt) for serving as auxiliary treating drug capable of easing acute kidney injury caused by chemotherapeutic drug, namely cis-platinum

A technology for acute kidney injury and glycyrrhetinate, which is applied in the field of pharmacotherapeutics and can solve problems such as limiting clinical application
CN106539803AInactive Publication Date: 2017-03-29ANHUI MEDICAL UNIV
0 Cites 6 Cited by

Patent Information

Authority / Receiving Office
CN · China
Current Assignee / Owner
ANHUI MEDICAL UNIV
Publication Date
2017-03-29
Estimated Expiration
Not applicable · inactive patent

Smart Images

  • Figure 1
    Figure 1
  • Figure 2
    Figure 2
  • Figure 3
    Figure 3
Patent Text Reader

Abstract

The invention belongs to the field of pharmacotherapeutics, and particularly relates to application of 18 beta-glycyrrhetinic acid (or salt) for serving as an auxiliary treating drug capable of easing acute kidney injury caused by a chemotherapeutic drug, namely cis-platinum, wherein the 18 beta-glycyrrhetinic acid (or salt) is one of the main components of liquorice. The cis-platinum serves as a commonly-used chemotherapy drug, and clinical application thereof is restricted by kidney toxicity thereof. The levels of creatinine and urea nitrogen in the acute kidney injury induced by the cis-platinum can be inhibited by the18 beta-glycyrrhetinic acid, expression of KIM-1 injured protein is lowered, and apoptosis of renal tubular epithelial cells caused by the cis-platinum is inhibited. According to the application of the 18 beta-glycyrrhetinic acid (or salt) for serving as the auxiliary treating drug capable of easing the acute kidney injury caused by the chemotherapeutic drug, namely the cis-platinum, the effect that the 18 beta-glycyrrhetinic acid has a protecting effect on the acute kidney injury caused by the cis-platinum is discovered for the first time, a mechanism of the 18 beta-glycyrrhetinic acid is related to inhibiting of apoptosis of the renal tubular epithelial cells, and a novel potential drug is provided for Chinese medicine anti-cancer adjuvant therapy.
Need to check novelty before this filing date? Find Prior Art

Description

technical field

[0001] The invention belongs to the field of pharmacotherapeutics, and discloses the application of 18β-glycyrrhetinic acid (or salt) as an adjuvant treatment drug for alleviating acute kidney injury caused by chemotherapy drug cisplatin. Background technique

[0002] The nephrotoxicity of clinical chemotherapy drugs has always been the bottleneck of tumor treatment. How to reduce the toxic and side effects of chemotherapy drugs is one of the focuses of research in the process of tumor treatment. Cisplatin (cis-dichlorodiammino platinum Ⅱ or Cisplatin, CP), as a widely used cytotoxic chemotherapy drug, has a good effect on a variety of tumors. The activity of cisplatin is related to the concentration of chloride ions. In the low-chloride environment of the intracellular fluid, the chloride ions in the cisplatin structure undergo hydration dissociation and are replaced by water to generate positively charged hydration complex ions, which undergo addition react...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More